je.st
news
Merck Presents New Pharmacokinetic Data on ISENTRESS (raltegravir) at 14th European AIDS Conference
2013-10-16 14:30:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. Company Confirms Development Program for Investigational Once Daily (QD) Dosing Regimen of ISENTRESS WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, is presenting pharmacokinetic data this week on investigational formulations of a once daily (QD) dose of ISENTRESS at the 14th European AIDS Conference (EACS), sponsored by the European AIDS Clinical Society. The meeting is currently taking place in Brussels, Belgium, Oct. 16-19, 2013. The poster presentation A Single Dose Food Effect Study of Raltegravir Formulations (Poster #PE10/17) will be presented Thursday, Oct. Language: English Contact: MerckMedia Contacts:Pam Eisele, 908-423-5042Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
conference
european
aids
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||